ST elevation myocardial infarction and non ST elevation myocardial infarction/unstable angina MedDRA version: 9.1 Level: LLT Classification code 10000920 Term: Acute myocardial infarction, subendocardial infarction MedDRA version: 9.1 Level: LLT Classification code 10000891 Term: Acute myocardial infarction MedDRA version: 9.1 Level: LLT Classification code 10002385 Term: Angina pectoris unstable
Conditions
Interventions
Trade Name: Reopro
Product Name: Reopro
Pharmaceutical Form: Concentrate for solution for infusion
Trade Name: Angiox
Product Name: Angiox
Pharmaceutical Form: Solution for infusion
Trade Name: inte
Sponsors
Sahlgrenska University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age over 18 years. 2. Patients with STEMI, treated with primary PCI or patients with NSTEMI treated with PCI. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Intolerance to abciximab, eptifibatide, tirofiban, ASA eller clopidogrel. Increased risk for bleedings Patients with prior hemmoragic stroke Patients with ischemic stroke the last 6 months Patients with gastrointestinal or genitourinary bleeding the last two months Patients with ongoing warfarin or oral thrombin inhibitor treatment Patients treated recently with thrombolysis (rescue PCI) History of Heparin induced trombocytopenia (HIT) Known platelet count =100.000 per deciliter Known hemoglobin level = 10mg per deciliter Known renal failure with serum creatinine levels over 200 µmol/L History of prior myocardial infarction History of medically treated angina pectoris History of prior PCI or CABG Patients presenting with cardiogenic shock Presence of systemic disease with a less than a year expected life duration Patient`s unweeling in participating in the study Difficulties in communication between the medical stuff and the patient, even due to language problems or due to the patients` disease status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare three different anticoagulation strategies during PCI in terms of platelet aggregation and neutrofiles activation;Secondary Objective: To compare three different anticoagulation strategies during PCI in terms of clinical efficacy and safety;Primary end point(s): Platelet activation measured with multiple electrode aggregometry immediately after PCI with TRAP as agonist. | — |
Countries
Sweden
Outcome results
None listed